Sort
82,697 grants matching “vaccine development”
THERAPEUTICS FOR EMERGING HUMAN ENTEROVIRUSES
$1,499,422Kandyma Sar · Hdt Bio Corporation · N01 · FY2022 · AI
ADVANCEMENT OF POTENT BROAD SPECTRUM ENTEROVIRUS THERAPEUTICS
$1,499,249Ingrid Persson · Integrated Research Associates, Llc · N01 · FY2022 · AI
Miami HIV/AIDS Clinical Therapeutic and Vaccine Trial Unit
$1,499,229Margaret A Fischl · University Of Miami School Of Medicine · U01 · FY2009 · AI
TAS::75 0849 - TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING A
$1,499,001Frank R. Jones · Etubics Corporation · N44 · FY2011 · CA
Structural Studies of Pattern Recognition Receptors
$1,498,876Tsan Xiao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies
$1,498,398Luis Manuel Branco · Zalgen Labs, Llc · R01 · FY2019 · AI
LcrV Plague Vaccine with Altered Immune Modulatory Properties
$1,498,357Olaf Schneewind · University Of Chicago · U01 · FY2007 · AI
Fox COBRE Phase II Admin Core
$1,498,202Joseph M Fox · University Of Delaware · P20 · FY2023 · GM
RNA TRASFECTED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
$1,497,862Duke University · P01 · FY2002 · CA
MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA)
$1,497,671Jeanette Coffin · Midwest Research Institute · N01 · FY2021 · AI
DEVELOPING A FRAMEWORK TO ADDRESS LEGAL, ETHICAL, REGULATORY, AND POLICY ISSUES FOR RESEARCH SPECIFIC TO PREGNANT AND LACTATING PERSONS
$1,497,220Robert Day · National Academy Of Sciences · N01 · FY2022 · OD
Clinical Research Support for the CCR
$1,496,927Thomas A Misteli · Division Of Basic Sciences - Nci · ZID · FY2021 · CA
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,496,654Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
COLUMBIA/ROCKEFELLER CENTER FOR AIDS RESEARCH
$1,496,652Columbia University Health Sciences · P30 · FY2001 · AI
improving outcomes after stem cell transplantation
$1,496,532Austin J Barrett · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
$1,496,446Michael A Pulsipher · Children'S Hospital Of Los Angeles · U01 · FY2018 · AI
Tfh and B cells in HIV/SIV pathogenesis and vaccination
$1,496,217Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
2/2 CCNY-MSKCC Partnership for Cancer Research, Education and Community Outreach
$1,496,000Tim Alan Ahles · Sloan-Kettering Inst Can Research · U54 · FY2024 · CA
Lambda Genetic Networks and Lambda Red-Mediated Recombination
$1,495,905Donald Court · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Influenza Viral Pathogenesis
$1,495,401Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Eliciting B cells to produce anti-HIV gp41 MPER-specific neutralizing antibodies
$1,495,269Ellis L Reinherz · Dana-Farber Cancer Inst · U19 · FY2013 · AI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models
$1,495,060Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Immunopharmacotherapy for Mitigating Opioid Addiction
$1,494,700Kim D Janda · Scripps Research Institute, The · UH3 · FY2018 · DA
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy
$1,494,670Pawel Kalinski · Roswell Park Cancer Institute Corp · P01 · FY2024 · CA
Immunology, virology, and epidemiology of flaviviruses and other emerging viruses
$1,494,560Leah Katzelnick · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI